This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Race Oncology Releases ‘Striking’ Interim Phase 2 AML Trial Results
Race Oncology (ASX:RAC) has announced positive interim clinical results from an ongoing investigator-initiated Phase II study of its core asset bisantrene in combination with fludarabine and clofarabine in R/R AML patients. Read more here.
-
Race Oncology Kicks Off Safety Studies For RC220
Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusion, RC220. The company has signed contracts with Attentive Science (USA) and Agilex Biolabs (Australia) to complete a package of…
-
Race Oncology Unveils Bisantrene’s Broad Anti-Cancer Potential In Latest Preclinical Studies
Race Oncology Ltd (ASX:RAC) has welcomed preclinical findings on the anti-cancer efficacy of bisantrene, which demonstrate its potential in enhancing the cancer-killing activity of the widely used drug doxorubicin across a diverse range of 143 human cancer cell lines. Read more here
-
The Australian reports on Race Oncology’s revised corporate strategy
Writing in The Australian, Stockhead reported on Race Oncology’s revised corporate strategy. They spoke to Race Oncology CEO and MD Damian Clarke-Bruce about how Race Oncology is working to put itself at the heart of cancer care. Read the full piece here.
-
Race Oncology Strategy Update Shareholder Q&A
Race Oncology CEO and MD Damian Clarke-Bruce and Chief Medical Officer Dr Michelle Rashford talked shareholders through Race’s refreshed corporate strategy and answered their questions during a webinar last week. Watch the full webinar here.
-
Proactive Investors reports on Race Oncology’s revised strategy
Proactive Investors reported on Race Oncology’s revised corporate strategy, designed to maximise the commercial potential of bisantrene. See the full report here.
-
August 2023 update
Race Oncology Limited (“Race”) is pleased to provide shareholders with a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential. Key highlights: Read the strategic update summary and investor presentation here. Non-Executive Chair, Mary Harney commented: “Through the course…
-
Proactive Investors reports on Race’s first half update
Proactive Investors reported on Race’s recent first half clinical programs update. Read the full story here.
-
April 2023 Update
Race Oncology is pleased to release a detailed commercial assessment of the market potential for Zantrene® as a cardio-protective agent or dual cardio-protective + anti-cancer in breast, endometrial and ovarian cancers.Key points from the research include: CEO and Managing Director, Damian Clarke-Bruce commented, “It is pleasing to now be able to share this complete research…